Background: Increased hepatocyte growth factor/MET signaling is associated with an aggressive phenotype and poor prognosis in triple-negative breast cancer (TNBC). We evaluated the benefit of adding onartuzumab, a monoclonal anti-MET antibody, to paclitaxel with/without bevacizumab in patients with TNBC.
introduction Triple-negative breast cancers (TNBCs) are associated with an aggressive clinical course and poorer outcome than other breast cancers [1, 2] . TNBC remains a significant challenge to treat; chemotherapy is effective in some cases, with pathologic complete response (pCR) rates of around 50% reported [3, 4] . However, TNBCs have a worse outcome overall, particularly if pCR is not achieved [1, 5] . The addition of bevacizumab to chemotherapy in patients with metastatic TNBC significantly increased objective response rate (ORR) and progression-free survival (PFS) versus chemotherapy alone, but the lack of an overall survival (OS) benefit led to controversy about the therapeutic indication [6] .
MET signaling plays a vital role in tissue remodeling and its dysregulation has been implicated in many tumors, affecting cell proliferation, invasion, metastasis, and survival [7] . The MET pathway is frequently activated in TNBCs and/or basal-like tumors [8] [9] [10] [11] [12] .
Onartuzumab (MetMab; Genentech, South San Francisco, CA) is a recombinant, humanized, monovalent, anti-MET monoclonal antibody, which selectively blocks ligand binding and hepatocyte growth factor (HGF)-dependent signaling [13] . Because the HGF/ MET pathway has been implicated in the upregulation of vascular endothelial growth factor (VEGF) expression, dual MET and VEGF inhibition may provide an improved clinical benefit. This phase II study evaluated the efficacy and safety of onartuzumab plus bevacizumab plus paclitaxel (OBP), and onartuzumab plus placebo plus paclitaxel (OP), relative to placebo plus bevacizumab plus paclitaxel (BP) in patients with TNBC.
methods study design
OAM4861g was a randomized, double-blind, placebo-controlled study in patients with metastatic or locally recurrent (LR) TNBC. Patients who discontinued paclitaxel for toxicity could continue onartuzumab/placebo and bevacizumab/placebo. Patients were randomized to treatment (1:1:1) using an interactive voice/ web-based system stratified according to the number of metastatic sites (<3 versus ≥3), line of therapy (first versus second), and disease-free interval for first-line patients (≤6 versus >6 months).
The protocol was approved by the institutional review board of each participating center and the study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Patients provided written informed consent.
patients
Eligibility criteria were ≥18 years; histologically confirmed TNBC; ≤1 prior therapy for metastatic TNBC; measurable/non-measurable metastatic/LR disease not amenable to resection with curative intent; Eastern Cooperative Oncology Group performance status ≤1; consent to providing tumor tissue; and adequate hematologic, renal, and liver function. Exclusion criteria were systemic anticancer therapy within 3 weeks before day 1, cycle 1; previous taxanes for metastatic breast cancer; prior antiangiogenic or anti-MET/anti-HGF therapy; prior endocrine or human epidermal growth factor receptor 2-directed therapy; or untreated central nervous system metastases.
assessments
Computed tomography scans were obtained at baseline and every two cycles. Disease status per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 was assessed by investigators.
Onartuzumab and bevacizumab serum samples were assessed centrally using validated enzyme-linked immunosorbent assays. Paclitaxel/6-OHpaclitaxel plasma samples were analyzed centrally using a validated liquid chromatography tandem mass spectrometry method.
Tumor tissue (archival permitted) was collected for confirmation of TNBC and evaluation of MET expression. MET immunohistochemistry (IHC) was carried out centrally with the CONFIRM SP44 anti-MET rabbit monoclonal primary antibody (Ventana Medical Systems, Inc., Tucson, AZ) on a Ventana Benchmark XT platform. Staining intensity was evaluated using an IHC scoring system [14] . MET positivity was defined as a score of 2+/3+ based on the 50% cutoff developed for non-small-cell lung cancer (NSCLC) [15] . The MET status was determined centrally after randomization and before unblinding. IHC for epidermal growth factor receptor (EGFR), cytokeratin 5, and phosphatase and tensin homolog (PTEN) was carried out on a Ventana autostainer using antibodies 3C6 (Ventana), AF 138 (Covance Biologics, Princeton, NJ), and 138G6 (Cell Signaling Technology, Beverley, MA), with CC1 retrieval conditions. Cases were scored using an H-score algorithm [16] . Formalin-fixed, paraffin-embedded (FFPE) sections were macrodissected to enrich for neoplastic tissue followed by RNA extraction [17] using the high-pure FFPE RNA Micro Kit (Roche Applied Sciences, Indianapolis, IN). NanoString gene expression data were collected using a custom 400-gene breast cancer panel for PAM50 analysis [18] .
statistical analysis
The primary end point was investigator-assessed PFS, defined as the time from randomization to PD/relapse (RECIST v1.1), or death on study from any cause, whichever occurred first. OS was defined as the time from randomization to death from any cause. Median PFS/OS were estimated by Kaplan-Meier methodology. For each pairwise comparison of the OBP or OP arm versus the BP arm, an estimate of the hazard ratio (HR) and 95% confidence interval (CI) was determined using a Cox regression model stratified by the randomization stratification factors. Log-rank test (stratified) was used to compare survival between the arms. ORR was defined as the proportion of patients with a complete or partial response on two consecutive assessments ≥4 weeks apart (RECIST v1.1); 95% CI were computed using the Blyth-Still-Casella method. Adverse events (AEs) were assessed using National Cancer Institute Common Terminology Criteria for Adverse Events (v 4.0). Onartuzumab concentrations were compared with simulated results based on a population pharmacokinetic (PK) model [19] . Bevacizumab concentrations were compared with predictions from a bevacizumab PK model [20] .
The study was designed to accrue ∼180 patients. Efficacy analyses were planned after 126 investigator-assessed PFS events. This trial was hypothesis generating and did not have power to detect minimum clinically meaningful differences between treatment arms. Based on 84 PFS events for the comparison of each onartuzumab-containing arm versus the BP arm, the study had 80% power to detect, at a one-sided significance level of 0.025, an HR of 0.54 for each onartuzumab-containing arm relative to the BP arm. No adjustments for multiple comparisons were made.
results patient demographics
From March 2011 to March 2013, 185 patients were randomized to receive OBP (n = 63), OP (n = 60), or BP (n = 62) (Figure 1 ). Baseline demographics were balanced across the arms ( Table 1) . The MET status was determined in 178 patients (96%), of whom 22 (12%) had MET-positive tumors (IHC 2+/3+). (Table 2) . Compared with BP, the risk of a PFS event was higher with OP (stratified HR, 1.74; 95% CI 1.13−2.68; P = 0.011) and similar with OBP (stratified HR, 1.08; 95% CI 0.69−1.70; P = 0.730) (Figure 2A ; Table 2 ).
Objective response was evaluated in 149 patients with measurable disease at baseline. ORR was 42.2% (95% CI 28.6−57.1) with OBP, 27.5% (95% CI 15.9−40.6) with OP, and 54.7% (95% CI 41.0−68.4) with BP ( Table 2) .
At the data cutoff date, 76 deaths (41.1%) were recorded: 27 with OBP, 26 with OP, and 23 with BP. Median OS was 14.7 months, 13.4 months, and 17.4 months, respectively (Table 2) . OS was numerically shorter with OBP (stratified HR, 1.36; 95% CI 0.75−2.46; P = 0.316) and OP (stratified HR, 1.92; 95% CI 1.03−3.59; P = 0.038), than with BP (Table 2; Figure 2B ).
exploratory end points
Exploratory analyses examined the effect of baseline characteristics on PFS (supplementary Figure S1 , available at Annals of Figure S2 , available at Annals of Oncology online). Compared with BP, the risk of a PFS event was higher with OP (stratified HR, 1.61; 95% CI 0.89−2.90) and similar with OBP (stratified HR, 1.05; 95% CI 0.54−2.04). Median OS was 14.7 months with OBP, 10.8 months with OP, and 14.6 months with BP. Compared with BP, the risk of an OS event was higher with OP (stratified HR, 1.72; 95% CI 0.77−3.81) and similar with OBP (stratified HR, 1.07; 95% CI 0.45−2.53), but these differences were not statistically significant. Basal-like tumors showed high EGFR and low PTEN expression (supplementary Figure S3 , available at Annals of Oncology online).
pharmacokinetics Mean serum onartuzumab concentrations were similar in the two onartuzumab-containing arms (supplementary Table S1 , available at Annals of Oncology online), and were consistent with simulated data (90% CI 154-583 µg/ml steady-state peak; 26.1-149 µg/ml steady-state trough). Observed bevacizumab serum concentrations were similar in the two bevacizumabcontaining arms; at steady-state, most fell within the 90% CI of the predicted concentration-time profile. Plasma paclitaxel/6-OH-paclitaxel concentrations were similar among treatment arms (not shown).
safety
Median dose intensity was 100% for onartuzumab and bevacizumab. Median paclitaxel dose intensity was 97.8%, 97.2%, and 93.5% in the BP, OP, and OBP arms, respectively.
Most common AEs in the onartuzumab-containing arms were peripheral edema, alopecia, and fatigue (Table 3) . Peripheral edema was reported by 58.1% and 58.6% of OBP and OP patients, respectively, versus 17.7% of BP patients. Alopecia, epistaxis, and diarrhea were the most frequent AEs in the bevacizumabcontaining arms.
Patients receiving OBP were most likely to have an AE leading to treatment withdrawal; most often peripheral edema that led to onartuzumab withdrawal (five patients; 8.1%). Serious AEs occurred in more patients receiving OBP than OP or BP (32% versus 22% versus 24%), as did Grade 3-5 AEs (71% versus 50% versus 61%) ( Table 3) . Five AEs resulted in death, three (4.8%) with OBP (sepsis, dural fistula, and Based on 149 randomized patients with measurable disease at baseline. BP, placebo plus bevacizumab plus paclitaxel; CR, complete response; HR, hazard ratio; NE, not estimable; OBP, onartuzumab plus bevacizumab plus paclitaxel; OP, onartuzumab plus placebo plus paclitaxel; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PR, partial response. Of the known AEs associated with bevacizumab, gastrointestinal perforation occurred in two patients (3.2%) receiving OBP, and venous thromboembolic events were reported in eight patients (12.9%) receiving OBP or BP, and in three patients (5.2%) receiving OP. Most common thromboembolic events were pulmonary embolism (11 patients; 6.0%) or deep vein thrombosis (six patients; 3.3%). Analyses according to MET IHC score were inconclusive owing to the low proportion of patients with MET-positive tumors.
Comparison of outcomes in the OBP and BP arms suggested no negative impact of onartuzumab in patients with MET-negative disease. The question of a positive treatment effect in patients with MET-positive tumors could not be answered and was not explained by dose intensity, PK, safety, or AE findings. An NSCLC trial of onartuzumab plus erlotinib also demonstrated a benefit for patients with MET-positive tumors but potentially worse outcome in MET-negative disease, which was not explained by patterns of PD, PK, or safety [15] . There are a number of hypotheses for the potentially deleterious effect of onartuzumab in MET-negative tumors. It is conceivable that alternative pathways of MET activation exist such that MET might act as a tumor suppressor in MET-negative disease and as an oncogene in MET-positive disease. Furthermore, the extent of VEGF and MET inhibition may differ between tumors with low and high MET expression. Alternatively, there may be a base level of MET signaling required to trigger apoptosis, but in patients with low MET expression levels there is a greater chance of the MET receptors being blocked by onartuzumab and thereby preventing HGF binding. No drug-drug interaction was evident when onartuzumab and bevacizumab were co-administered with paclitaxel. The incidence and severity of AEs were similar across treatment arms, despite a slightly lower dose intensity of docetaxel in the OBP arm. Peripheral edema was increased in both onartuzumabcontaining arms versus the control arm, as seen in NSCLC [15] , although the incidence was much higher in our study (∼60% versus ∼20% NSCLC). A higher rate of AEs leading to withdrawal and of serious AEs were recorded with OBP relative to the other treatments. Most deaths were due to the patients' underlying TNBC.
Exploratory PAM50 analysis revealed that 68% of the tumor samples were basal-like (which is in-line with expectations), with high EGFR expression and low PTEN expression, suggesting activation of alternative signaling pathways. These findings highlight the need for biomarker-guided trials in TNBC to assess the effect of targeted treatment.
In conclusion, the addition of onartuzumab to BP or to paclitaxel did not improve PFS, OS, or ORR compared with BP in patients with advanced TNBC and predominantly METnegative tumors. 
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